Association of plasma uric acid with ischaemic heart disease and blood pressure: Mendelian randomization analysis of two large cohorts

BMJ (Online)

Volumn 347, Issue 7919, 2013, Pages

  Palmer, Tom M ^a   Nordestgaard, Børge G ^c,d,e   Benn, Marianne ^c,d   Tybjarg Hansen, Anne ^c,d,e,f   Smith, George Davey ^b   Lawlor, Debbie A ^b   Timpson, Nicholas J ^b  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e FREDERIKSBERG HOSPITAL   (Denmark)

^f Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

URIC ACID;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DENMARK; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; FTO GENE; GENE; GENETIC SCREENING; GENOTYPE; HUMAN; HYPERURICEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MC4R GENE; MENDELIAN RANDOMIZATION ANALYSIS; OBSERVATIONAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SLC2A9 GENE; SYSTOLIC BLOOD PRESSURE; TMEM18 GENE; URIC ACID BLOOD LEVEL; WEIGHT GAIN;

ADULT; AGED; BLOOD PRESSURE; BODY MASS INDEX; DENMARK; FEMALE; HUMANS; HYPERURICEMIA; MALE; MENDELIAN RANDOMIZATION ANALYSIS; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; URIC ACID;

EID: 84881442965     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f4262     Document Type: Article

References (45)

1. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 1981;78:6858-62. (Pubitemid 12216861)
2. Phay JE, Hussain HB, Moley JF. Cloning and expression analysis of a novel member of the facilitative glucose transporter family, SLC2A9 (GLUT9). Genomics 2000;66:217-20. (Pubitemid 30429757)
3. Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, Palmer CNA, et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008;40:437-42. (Pubitemid 351450879)
4. Wu X, Muzny DM, Chi Lee C, Thomas Caskey C. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 1992;34:78-84.
5. Nesse RM, Williams GC. Evolution and healing: the new science of Darwinian medicine. Phoenix, 1996.
6. Liese AD, Hense HW, Lowel H, Doring A, Tietze M, Keil U. Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. Epidemiology 1999;10:391-7. (Pubitemid 29288237)
7. Alderman M, Aiyer KJV. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004;20:369-79. (Pubitemid 38339177)
8. Sundstrom J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005;45:28-33. (Pubitemid 40066409)
9. Perlstein TS, Gumieniak O, Williams GH, Sparrow D, Vokonas PS, Gaziano M, et al. Uric acid and the development of hypertension. Hypertension 2006;48:1031-6.
10. Bos MJ, Koudstaal PJ, Hofman A, Witteman JCM, Breteler MMB. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke 2006;37:1503-7. (Pubitemid 44305733)
11. Deveci OS, Kabakci G, Okutucu S, Tulumen E, Aksoy H, Kaya EB, et al. The association between serum uric acid level and coronary artery disease. Int J Clin Pract 2010;64:900-7.
12. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971-1992. JAMA 2000;283:2404-10. (Pubitemid 30257539)
13. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Care Res 2009;61:885-92.
14. Meisinger C, Koenig W, Baumert J, Doring A. Uric acid levels are associated with all-cause and cardiovascular disease mortality independent of systemic inflammation in men from the general population: the MONICA/KORA cohort study. Arterioscler Thromb Vasc Biol 2008;28:1186-92.
15. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res 2010;62:170-80.
16. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003;41:1183-90. (Pubitemid 36706063)
17. Davey Smith G, Ebrahim S. 'Mendelian Randomisation': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003;32:1-22. (Pubitemid 36503465)
18. Burgess S, Butterworth A, Malarstig A, Thompson SG. Use of Mendelian randomisation to assess potential benefit of clinical intervention. BMJ 2012;345:e7325.
19. Wallace C, Newhouse SJ, Braund P, Zhang F, Tobin M, Falchi M, et al. Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am J Hum Genet 2008;82:139-49. (Pubitemid 351735954)
20. Wright AF, Rudan I, Hastie ND, Campbell H. A 'complexity' of urate transporters. Kidney Int 2010;78:446-52.
21. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298:299-308. (Pubitemid 47080484)
22. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. J Am Coll Cardiol 2007;50:2173-95. (Pubitemid 350123680)
23. Sethi AA, Nordestgaard BG, Agerholm-Larsen B, Frandsen E, Jensen G, Tybjaerg-Hansen A. Angiotensinogen polymorphisms and elevated blood pressure in the general population: the Copenhagen City Heart Study. Hypertension 2001;37:875-81. (Pubitemid 32221607)
24. Tobin MD, Sheehan NA, Scurrah KJ, Burton PR. Adjusting for treatment effects in studies of quantitative traits: antihypertensive therapy and systolic blood pressure. Stat Med 2005;24:2911-35. (Pubitemid 41419179)
25. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61. (Pubitemid 41781828)
26. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet 2010;42:937-48.
27. Thomas DC, Lawlor DA, Thompson JR. Re: Estimation of bias in nongenetic observational studies using Mendelian triangulation by Bautista et al. Ann Epidemiol 2007;17:511-3. (Pubitemid 46938657)
28. Angrist JD, Imbens GW. Two-stage least squares estimation of average causal effects in models with variable treatment intensity. J Am Stat Soc 1995;90:431-42.
29. Harris R. metan: fixed- and random-effects meta-analysis. Stata J 2008;8:3-28.
30. Timpson NJ, Nordestgaard BG, Harbord RM, Zacho J, Frayling TM, Tybjarg-Hansen A, et al. C-reactive protein levels and body mass index: elucidating direction of causation through reciprocal Mendelian randomization. Int J Obes 2011;35:300-8.
31. Prospective Studies Collaboration, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009;373:1083-96.
32. Zheng W, McLerran DF, Rolland B, Zhang X, Inoue M, Matsuo K, et al. Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med 2011;364:719-29.
33. Timpson NJ, Harbord R, Davey Smith G, Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. Does greater adiposity increase blood pressure and Hypertension risk? Mendelian randomization using the FTO/MC4R genotype. Hypertension 2009;54:84-90.
34. Nordestgaard BG, Palmer TM, Benn M, Zacho J, Tybjaerg-Hansen A, Davey Smith G, et al. The effect of elevated body mass index on ischemic heart disease risk: causal estimates from a Mendelian randomisation approach. PLoS Med 2012;9:e1001212.
35. Brandstatter A, Kiechl S, Kollerits B, Hunt SC, Heid IM, Coassin S, et al. Sex-specific association of the putative fructose transporter slc2a9 variants with uric acid levels is modified by BMI. Diabetes Care 2008;31:1662-7.
36. Lyngdoh T, Vuistiner P, Marques-Vidal P, Rousson V, Waeber Gr, Vollenweider P, et al. Serum uric acid and adiposity: deciphering causality using a bidirectional Mendelian randomization approach. PLoS One 2012;7:e39321.
37. Ishizaka N, Ishizaka Y, Toda A, Tani M, Koike K, Yamakado M, et al. Changes in waist circumference and body mass index in relation to changes in serum uric acid in Japanese individuals. J Rheumatol 2010;37:410-6.
38. Stark K, Reinhard W, Grassl M, Erdmann J, Schunkert H, Illig T, et al. Common polymorphisms influencing serum uric acid levels contribute to susceptibility to gout, but not to coronary artery disease. PLoS One 2009;4:e7729.
39. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999;131:7-13. (Pubitemid 29310011)
40. Strasak A, Ruttmann E, Brant L, Kelleher C, Klenk J, Concin H, et al. Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83 683 Austrian men. Clin Chem 2008;54:273-84. (Pubitemid 351302628)
41. McKeigue PM, Campbell H, Wild S, Vitart V, Hayward C, Rudan I, et al. Bayesian methods for instrumental variable analysis with genetic instruments (Mendelian randomization): example with urate transporter SLC2A9 as instrumental variable for effect of urate levels on metabolic syndrome. Int J Epidemiol 2010;39:907-18.
42. Caulfield MJ, Munroe PB, O'Neill D, Witkowska K, Charchar FJ, Doblado M, et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med 2008;5:e197.
43. Yang Q, Kottgen A, Dehghan A, Smith AV, Glazer NL, Chen MH, et al. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet 2010;3:523-30.
44. Parsa A, Brown E, Weir MR, Fink JC, Shuldiner AR, Mitchell BD, et al. Genotype-based changes in serum uric acid affect blood pressure. Kidney Int 2012;81:502-7.
45. Davey Smith G, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol 2004;33:30-42. (Pubitemid 38528650)